Table 1.

Levels of immunosuppression

High-level immunosuppression

Low-level immunosuppression

•Treatment ≥ 20 mg/day of prednisone or equivalent for ≥ 2 weeks and within 3 months of stopping •Treatment with 6-mercaptopurine ≥ 1.5 mg/kg/day Azathioprine ≥ 3 mg/kg/day Methotrexate ≥ 0.4 mg/kg/week or discontinuation within 3 months •Treatment with rituximab, infliximab, golimumab adalimumab, certolizumab pegol, natalizumab, or vedolizumab, or discontinued within 3 months •Patients with HIV infection with a CD4 T-lymphocyte count < 200 cells/mm3 •Patients with combined primary immunodeficiency disorder (e.g. severe combined immunodeficiency) •Patients receiving cancer chemotherapy, within 2 months after solid organ transplantation

•Treatment < 20 mg/day of prednisone or equivalent for ≥ 2 weeks •Treatment with 6-mercaptopurine < 1.5 mg/kg/day Azathioprine < 3.0 mg/kg/day Methotrexate < 0.4 mg/kg/week or discontinuation within 3 months •Patients with significant protein-calorie malnutrition •Asymptomatic HIV-infected patients with CD4 T-lymphocyte counts of 200–499 cells/mm3

HIV human immunodeficiency virus